GlaxoSmithKline PLC
25 May 2005
Issued - Wednesday 25th May 2005, London - LSE Announcement
GlaxoSmithKline plc
Announces Change to the Board's Remuneration Committee
The Board has appointed Dr Ronaldo Schmitz a member of the Remuneration
Committee, with immediate effect.
This brings the membership of the Committee to four Non-Executive Directors all
of whom are independent
The attached list shows the membership of the Board's Committees.
S M Bicknell
Company Secretary
25th May 2005
Board Committee Membership
with effect from 25th May 2005.
Board Committee Committee Chairman Members
Audit Dr Ronaldo Schmitz Sir Deryck Maughan
Sir Ian Prosser
Sir Robert Wilson
Remuneration Sir Robert Wilson Mr H Lawrence Culp
Sir Crispin Davis
Dr Ronaldo Schmitz
Nominations Sir Christopher Gent Sir Ian Prosser
Dr Ronaldo Schmitz
Corporate Responsibility Sir Christopher Gent Sir Ian Prosser
Dr Lucy Shapiro
GSK Enquiries:
UK Media enquiries: Philip Thomson (020) 8047 5502
David Mawdsley (020) 8047 5502
Chris Hunter-Ward (020) 8047 5502
Alice Hunt (020) 8047 5502
US Media enquiries: Nancy Pekarek (215) 751 7709
Mary Anne Rhyne (919) 483 2839
Patricia Seif (215) 751 7709
European Analyst/Investor enquiries: Duncan Learmouth (020) 8047 5540
Anita Kidgell (020) 8047 5542
Jen Hill (020) 8047 5543
US Analyst/ Investor enquiries: Frank Murdolo (215) 751 7002
Tom Curry (215) 751 5419
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.